|
Age, median (IQR), year
|
62.5 (51.0–79.0)
|
|
BMI, median (IQR), kg/m2
|
25.4 (23.6–29.5)
|
|
ASA score, median (IQR)
|
2.0 (1.0–2.0)
|
|
PSA, median (IQR), ng/ml
|
28.85 (11.5–150.8)
|
|
Prostate volume, median (IQR), cc
|
38.6 (23.5–110.0)
|
|
Biopsy Gleason score
| |
|
6
|
4 (2.1%)
|
|
7
|
58 (30.9%)
|
|
8
|
82 (43.6%)
|
|
≥ 9
|
44 (23.4%)
|
|
Clinical stage
| |
|
High-risk localized (≤ cT2c)
|
54 (28.7%)
|
|
High-risk locally advanced
|
134 (71.3%)
|
|
cT3a
|
72 (38.3%)
|
|
≥ cT3b
|
62 (33.0%)
|
|
cN1
|
10 (5.3%)
|
|
SHIM score, median (IQR)
|
16.5 (7–24)
|
|
IPSS score, median (IQR)
|
14.5 (4–28)
|
|
Charlson comorbidity index
| |
|
0
|
148 (78.7%)
|
|
1–2
|
35 (18.6%)
|
|
≥ 3
|
5 (2.7%)
|
